Specify a stock or a cryptocurrency in the search bar to get a summary
SQZ Biotechnologies Company
SQZBSQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts. Address: 200 Arsenal Yards Boulevard, Watertown, MA, United States, 02472
Analytics
WallStreet Target Price
22 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures SQZB
Dividend Analytics SQZB
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History SQZB
Stock Valuation SQZB
Financials SQZB
Results | 2019 | Dynamics |